Procter & Gamble Health Share Price
07 Aug, 2026 3:54 PM (IST)
Procter & Gamble Health Performance
- Today's Low
- ₹6,009
- Today's High
- ₹6,170
- 52 Week Low
- ₹4,707
- 52 Week High
- ₹6,975
- Open Price₹6,060
- Previous Close₹6,068
- Volume26,057
- 50 DMA₹6,325.60
- 100 DMA₹6,030.80
- 200 DMA₹5,819.90
Procter & Gamble Health Chart
Investment Returns
- Over 1 Month -1.88%
- Over 3 Month + 14.74%
- Over 6 Month + 18.39%
- Over 1 Year -3.13%
Smart Investing Starts Here Start SIP with Procter & Gamble Health for Steady Growth!
Procter & Gamble Health Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 28.6
- PEG Ratio
- 1.5
- Market Cap Cr
- 10,200
- P/B Ratio
- 19.4
- Average True Range
- 200.6
- EPS
- 215
- Dividend Yield
- 3.3
- MACD Signal
- -35.4
- RSI
- 35.46
- MFI
- 5.76
Latest Stock News Updates
<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Procter & Gamble Health announced Q1FY27 results</strong></span></h3> <p><strong>Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Revenue from Operations:</strong> The company reported revenue from operations of Rs 36,371 lakh in Q1FY27, representing a growth of 7.37% compared to Rs 33,874 lakh in Q1FY26. On a sequential basis, revenue decreased by 1.82% from Rs 37,045 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Income:</strong> Total income for Q1FY27 stood at Rs 36,759 lakh, an increase of 7.24% over Rs 34,277 lakh in Q1FY26. Compared to Q4FY26, total income saw a marginal decline of 1.83% from Rs 37,445 lakh.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Profit Before Tax (PBT):</strong> The company achieved a PBT of Rs 12,912 lakh in Q1FY27, a significant increase of 45.39% from Rs 8,881 lakh in Q1FY26. Sequentially, PBT declined by 3.07% from Rs 13,321 lakh in Q4FY26. The Q1FY27 PBT includes an exceptional gain of Rs 3,180 lakh.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Net Profit for the Period:</strong> Net profit stood at Rs 9,615 lakh in Q1FY27, registering a growth of 45.29% compared to Rs 6,618 lakh in Q1FY26. On a QoQ basis, net profit grew by 1.64% from Rs 9,460 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Total Comprehensive Income:</strong> The total comprehensive income for Q1FY27 was Rs 9,646 lakh, up by 47.20% from Rs 6,553 lakh in Q1FY26 and up 5.23% from Rs 9,167 lakh in Q4FY26.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Earnings Per Share (EPS):</strong> Basic and diluted EPS (after exceptional items) for Q1FY27 was Rs 57.92, compared to Rs 39.87 in Q1FY26 and Rs 56.99 in Q4FY26.</li> </ul> <p><strong>Business Highlights</strong></p> <ul> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Segment Performance:</strong> The company operates in a single primary reportable segment, namely "Pharmaceuticals," as identified under Ind AS 108.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Exceptional Item:</strong> During Q1FY27, the company sold its office premises property in Worli for a total consideration of Rs 3,334 lakh. With the carrying amount of the property at Rs 154 lakh, the transaction resulted in an exceptional gain of Rs 3,180 lakh.</li> <li _ngcontent-ng-c1006311636=""><strong _ngcontent-ng-c1006311636="">Audit Opinion:</strong> The statutory auditors, M/s Haribhakti & Co. LLP, have issued a Limited Review Report with an unmodified conclusion on the financial results for the quarter ended June 30, 2026.</li> </ul> <p><strong>Milind Thatte, Managing Director, P&G Health India, said</strong>, “We are happy to start the Financial Year 2026-2027 on a strong note, carrying forward the growth momentum of the previous fiscal. We delivered a strong quarter with sustained top-line and bottom-line growth. This growth is enabled by the consumer response to our science-backed superior innovations, new consumer communication initiatives and strengthened go-to-market and supply chain capabilities.</p> <p>We are delivering balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.”</p> <p><a class="lb" href="/get-document/post/pdf/5768690/" target="_blank">Result PDF</a></p>
- Trendlyne
- 3 days 14 hours ago
Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.
- BSE India
- 3 days 14 hours ago
Unaudited Financial Results for the Quarter ended June 30, 2026
- BSE India
- 3 days 14 hours ago
Procter & Gamble Health Financials
Procter & Gamble Health Technicals
EMA & SMA
- Bearish Moving Average 11
- Bullish Moving Average 5
- 20 Day
- ₹6,497.90
- 50 Day
- ₹6,325.60
- 100 Day
- ₹6,030.80
- 200 Day
- ₹5,819.90
Resistance and Support
- R3 6,367.70
- R2 6,268.80
- R1 6,206.70
- S1 6,045.70
- S2 5,946.80
- S3 5,884.70
Procter & Gamble Health Corporate Actions - Bonus, Splits, Dividends
About Procter & Gamble Health
Procter & Gamble Health is in the business of manufacturing and marketing of pharmaceuticals. View More- NSE Symbol
- PGHL
- BSE Symbol
- 500126
- ISIN
- INE199A01012
Similar Stocks to Procter & Gamble Health
Popular Stocks
Procter & Gamble Health FAQs
Procter & Gamble Health share price is ₹6,144 As on 10 August, 2026 | 04:39
The Market Cap of Procter & Gamble Health is ₹10199.5 Cr As on 10 August, 2026 | 04:39
The P/E ratio of Procter & Gamble Health is 28.6 As on 10 August, 2026 | 04:39
The PB ratio of Procter & Gamble Health is 19.4 As on 10 August, 2026 | 04:39
The 52 week High & Low of Procter & Gamble Health is ₹6975/₹4707 respectively As on 10 August, 2026 | 04:39
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.